RestoreSensor Study
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to gather clinical information on subjects' experiences with and without the use of the new feature of the RestoreSensor implantable neurostimulator (INS).
| Condition | Intervention |
|---|---|
|
Chronic Pain |
Device: RestoreSensor Neurostimulation System |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | RestoreSensor Study |
- Percentage of Subjects With Improved Pain Relief and/or Convenience During the AdaptiveStim Programming Arm Relative to the Manual Programming Arm [ Time Frame: 16 weeks post-implant ] [ Designated as safety issue: No ]After subjects experienced both AdaptiveStim and manual programming at 16 weeks post-implant, subjects were asked to compare pain relief and convenience when they had AdaptiveStim ON to AdaptiveStim OFF in two separate domains using two 5-point Likert scales. The outcome measure for the primary objective is the percentage of subjects who report improved pain relief with no loss of convenience or improved convenience with no loss of pain relief during the AdaptiveStim programming arm relative to the manual programming arm. These subjects were considered successful for the primary objective.
- Percentage of Subjects With Worsened Pain Relief When Using AdaptiveStim Compared to Manual Programming [ Time Frame: 16 weeks post-implant ] [ Designated as safety issue: No ]The pain relief question was a 5-point Likert scale question comparing pain relief when using AdaptiveStim programming relative to manual programming after subjects finished both programming periods. The choices were much worse pain relief with AdaptiveStim, somewhat worse pain relief with AdaptiveStim, no difference in pain relief, somewhat better pain relief with AdaptiveStim, and much better pain relief with AdaptiveStim. Subjects who had worsening pain relief were defined as subjects who responded "much worse pain relief with AdaptiveStim" or "somewhat worse pain relief with AdaptiveStim".
- Manual Adjustments Presented as Button Presses [ Time Frame: Baseline, 10 weeks and 16 weeks post-implant ] [ Designated as safety issue: No ]The number of individual adjustments, ie, button presses, were recorded automatically in the patient programmer, which was specifically designed for this study. The number of button presses per day for manual patient programmer adjustments during the manual programming arm and the AdaptiveStim programming arm of the study were compared.
- NPRS Scores From Baseline to Follow-up Visits at 10 Weeks and 16 Weeks Post-implant [ Time Frame: Baseline, 10 weeks and 16 weeks post-implant ] [ Designated as safety issue: No ]The 11-point (ie, 0-10) numeric rating scale of pain intensity (NPRS) was used to assess the overall pain at baseline and follow-up visits. In the pain diary, subjects were presented a numeric scale with numbers from 0 to 10, with 0 meaning "No pain" and 10 meaning "Pain as bad as you can imagine," accompanied by the instructions "Please rate your pain by indicating the number that best describes your pain on average in the last 24 hours." The subjects were asked to complete a diary for 7 consecutive days before implant, 10 weeks, and 16 weeks post-implant visits.
| Enrollment: | 79 |
| Study Start Date: | April 2010 |
| Study Completion Date: | January 2011 |
| Primary Completion Date: | January 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| 6-week AdaptiveStim followed by 6-week manual programming |
Device: RestoreSensor Neurostimulation System
Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned "ON" and manual when the AdaptiveStim feature of the device is turned "OFF".
|
| 6-week manual followed by 6-week AdaptiveStim programming |
Device: RestoreSensor Neurostimulation System
Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned "ON" and manual when the AdaptiveStim feature of the device is turned "OFF".
|
Detailed Description:
This study is a multi-center, prospective, open-label, randomized, crossover study that is designed to gather clinical information on subjects' experiences with the use of the new feature of the RestoreSensor implantable neurostimulator. Current spinal cord stimulators for chronic intractable pain stimulate targeted nerves along the spine using electrical impulses. The stimulation interferes with the transmission of pain signals to the brain replacing painful sensations with a tingling sensation called paresthesia. Variation in the intensity of neurostimulation with body position is a challenge for some patients implanted with conventional spinal cord stimulation systems because positional changes may result in overstimulation or understimulation. Patients need to manually adjust their stimulation using the patient programmer to maintain their comfort level during position changes. The AdaptiveStim feature of the RestoreSensor neurostimulator was developed to address this challenge by improving pain relief and/or convenience relative to manual programming adjustments.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Meets the indications as an appropriate surgical candidate (after successful SCS screening trial) for implant of a neurostimulation system for spinal cord stimulation (SCS) treatment of trunk and/or limb pain, per labeled indications
- 18 years of age or older
- Willing and able to attend visits and comply with the study protocol
- Capable of using the patient programmer and recharging the neurostimulator (INS), able to read and answer questionnaires in English, without assistance of a caregiver
- Males and non-pregnant females
Exclusion Criteria:
- Has had a prior implantable SCS neurostimulation system
- Currently enrolled, or plans to enroll in another investigational device or drug trial during the study
- Has unresolved legal issues related to their pain condition for which they would be receiving neurostimulation
- Requires cervical placement of leads.
Contacts and Locations| United States, Alabama | |
| Huntsville, Alabama, United States, 35801 | |
| United States, California | |
| Oceanside, California, United States, 92056 | |
| United States, Minnesota | |
| Edina, Minnesota, United States, 55435 | |
| United States, Nevada | |
| Las Vegas, Nevada, United States, 89149 | |
| United States, New Jersey | |
| Voorhees, New Jersey, United States, 08043 | |
| United States, Oregon | |
| Eugene, Oregon, United States, 97401 | |
| United States, Texas | |
| Dallas, Texas, United States, 75237 | |
| San Antonio, Texas, United States, 78258 | |
| San Antonio, Texas, United States, 78229 | |
| United States, Utah | |
| Salt Lake City, Utah, United States, 84106 | |
More Information
No publications provided by MedtronicNeuro
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | MedtronicNeuro |
| ClinicalTrials.gov Identifier: | NCT01106404 History of Changes |
| Other Study ID Numbers: | 1651 |
| Study First Received: | April 2, 2010 |
| Results First Received: | January 12, 2012 |
| Last Updated: | August 17, 2012 |
| Health Authority: | United States: Food and Drug Administration |
ClinicalTrials.gov processed this record on May 21, 2013